Abstract

Pulmonary thromboembolism (PE) is found commonly in forensic pathology practice, as it typically causes sudden death. It is attributed to a wide variety of predominantly acquired etiologies. Although likely etiologically multifactorial, some common proximate causes include: surgery, pregnancy, injury, inactivity of any cause, cancer, obesity, or serum hyperviscosity. On occasion, no apparent predisposing condition is identified. In these instances, occult hereditary thrombophilias may play a causal role. Deaths referred to the Office of Chief Medical Examiner (OCME) of New York City between December, 2000 and September, 2003 and due to PE were retrospectively reviewed. Molecular analysis (FRET) was performed on selected cases for three common hereditary thrombophilias: mutations in factor V Leiden (FVL), prothrombin G20210A (PT), and methylenetetrahydrofolate reductase (MTHFR).During the study period, 124 of 15,280 deaths were primarily attributable to PE. Of those, 34 were selected for molecular analysis. One or more mutations were detected in 35% of those, five of which were clearly causally related to death. Given the potential benefits to surviving family members, our data indicate that postmortem molecular testing for the common hereditary thrombophilias is warranted in at least selected cases.

References

1.
College of American Pathologists Consensus Conference XXXVI: diagnostic issues in Thrombophilia
.
Arch Pathol Lab Med
 0003-9985
2002
;
126
(
11
):
1277
433
.
2.
Seligsohn
U
,
Lubetsky
A
.
Genetic susceptibility to venous thrombosis
.
N Engl J Med
 0028-4793
2001
;
344
(
16
):
1222
31
.
3.
Bertina
RM
,
Koeleman
BP
,
Koster
T
,
Rosendaal
FR
,
Dirven
RJ
,
de Ronde
H
, et al
Mutation in blood coagulation factor V associated with resistance to activated protein C
.
Nature
 0028-0836
1994
;
369
(
6475
):
64
7
.
4.
Poort
SR
,
Rosendaal
FR
,
Reitsma
PH
,
Bertina
RM
.
A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
.
Blood
 0006-4971
1996
;
88
(
10
):
3698
703
.
5.
Frosst
P
,
Blom
HJ
,
Milos
R
,
Goyette
P
,
Sheppard
CA
,
Matthews
RG
, et al
A candidate genetic risk factorfor vascular disease: a common mutation in methylenetetrahydrofolate reductase
.
Nat Genet
 1061-4036
1995
;
10
(
1
):
111
3
.
6.
Miller
EJ
,
Marques
MB
,
Simmons
GT
.
Etiology of pulmonary thromboembolism in the absence of commonly recognized risk factors
.
Am J Forensic Med Pathol
 0195-7910
2003
;
24
(
4
):
329
33
.
7.
Andrew
TA
,
Fairweather
R
.
Prothrombin G20210A mutation and sudden death
.
Am J Forensic Med Pathol
 0195-7910
2003
;
24
(
4
):
377
80
.
8.
Van Cott
EM
,
Laposata
M
,
Prins
MH
.
Laboratory evaluation of hypercoagulability with venous or arterial thrombosis
.
Arch Pathol Lab Med
 0003-9985
2002
;
126
(
11
):
1281
95
.
9.
Brenner
BR
,
Nowak-Gottl
U
,
Kosch
A
,
Manco-Johnson
M
,
Laposata
M
.
Diagnostic studies for thrombophilia in women on hormonal therapy and during pregnancy, and in children
.
Arch Pathol Lab Med
 0003-9985
2002
;
126
(
11
):
1296
303
.
10.
Press
RD
,
Bauer
KA
,
Kujovich
JL
,
Heit
JA
.
Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders
.
Arch Pathol Lab Med
 0003-9985
2002
;
126
(
11
):
1304
18
.
11.
McGlennen
RC
,
Key
NS
.
Clinical and laboratory management of the prothrombin G20210A mutation
.
Arch Pathol Lab Med
 0003-9985
2002
;
126
(
11
):
1319
25
.
12.
Key
NS
,
McGlennen
RC
.
Hyperhomocyst(e)inemia and Thrombophilia
.
Arch Pathol Lab Med
 0003-9985
2002
;
126
(
11
):
1367
75
.
13.
Welch
GN
,
Loscalzo
J
.
Homocysteine and atherothrombosis
.
N Engl J Med
 0028-4793
1998
;
338
(
15
):
1042
50
.
14.
Wang
X
.
A theory for the mechanism of homocysteine-induced vascular pathogenesis
.
Med Hypotheses
 0306-9877
1999
;
53
(
5
):
386
94
.
15.
Makris
M
.
Hyperhomocysteinemia is a risk factor for venous and arterial thrombosis
.
Br J Haematol
 0007-1048
1998
;
101
Suppl
1
:
18
20
.
16.
Hankey
GJ
,
Eikelboom
JW
.
Homocysteine and vascular disease
.
Lancet
 0140-6736
1999
;
354
(
9176
):
407
13
.
17.
Tsai
MY
.
Moderate hyperhomocysteinemia and cardiovascular disease
.
J Lab Clin Med
 0022-2143
2000
;
135
(
1
):
16
25
.
18.
Check
W
.
Mutations add up to thrombophilic risk
.
CAP Today
2002
;
16
(
1
):1.
19.
Heit
JA
,
Silverstein
MD
,
Mohr
DN
,
Petterson
TM
,
Lohse
CM
,
O'Fallon
WM
, et al
The epidemiology of venous thromboembolism in the community
.
Thromb Haemost
 0340-6245
2001
;
86
(
1
):
452
63
.
20.
Vandenbroucke
JP
,
Rosing
J
,
Bloemenkamp
KW
,
Middeldorp
S
,
Helmerhorst
FM
,
Bouma
BN
, et al
Oral contraceptives and the risk of venous thrombosis
.
N Engl J Med
 0028-4793
2001
;
344
(
20
):
1527
35
.
21.
Middeldorp
S
,
Meijers
JC
,
van den Ende
AE
,
van Enk
A
,
Bouma
BN
,
Tans
G
, et al
Effects on coagulation of levonorgestrel- and desogestrel- containing low dose oral contraceptives: a cross-over study
.
Thromb Haemost
 0340-6245
2000
;
84
(
1
):
4
8
.
22.
Girolami
A
,
Vianello
F
The significance or nonsignificance of the G to A 20210 prothrombin polymorphism
.
Clin Appl Thromb Hemost
2000
;
6
(
4
):
239
40
.
23.
Gerhardt
A
,
Scharf
RE
,
Beckmann
MW
,
Struve
S
,
Bender
HG
,
Pillny
M
, et al
Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium
.
N Engl J Med
 0028-4793
2000
;
342
(
6
):
374
80
.
24.
Salomon
O
,
Steinberg
DM
,
Zivelin
A
,
Gitel
S
,
Dardik
R
,
Rosenberg
N
, et al
Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment
.
Aterioscler Thromb Vasc Biol
 1079-5642
1999
;
19
(
3
):
511
8
.
25.
Hoibraaten
E
,
Abdelnoor
M
,
Sandset
PM
.
Hormone replacement therapy with estradiol and risk of venous thromboembolism—a population based case-control study
.
Thromb Haemost
 0340-6245
1999
;
82
(
4
):
1218
21
.
26.
DiSiena
MR
,
Intres
R
,
Carter
DJ
.
Factor V Leiden and pulmonary embolism in a young woman taking an oral contraceptive
.
Am J Forensic Med Pathol
 0195-7910
1998
;
19
(
4
):
362
7
.
27.
Kwiatkowski
RW
,
Lyamichev
V
,
de Arruda
M
,
Neri
B
.
Clinical, genetic, and pharmacogenetic applications of the Invader assay
.
Mol Diagn
1999
;
4
(
4
):
353
64
.
28.
Lapostolle
F
,
Surget
V
,
Borron
SW
,
Desmaizieres
M
,
Sordelet
D
,
Lapandry
C
, et al
.
Severe pulmonary embolism associated with air travel
.
N Engl J Med
 0028-4793
2001
;
345
(
11
):
779
83
.
29.
Ansell
JE
.
Air travel and venous thromboembolism—is the evidence in?
N Engl J Med
 0028-4793
2001
;
345
(
11
):
828
9
.
30.
Koster
T
,
Rosendaal
FR
,
de Ronde
H
,
Briet
E
,
Vandenbroucke
JP
,
Bertina
RM
.
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
.
Lancet
 0140-6736
1993
;(
8886–8887
):
1503
6
.
31.
Rosendaal
FR
.
Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis
.
Thromb Haemost
 0340-6245
1997
;
78
(
1
):
1
6
.
32.
Dahlback
B
,
Hildebrand
B
.
Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V
.
Proc Natl Acad Sci USA
 0027-8424
1994
;
91
(
4
):
1396
400
.
33.
Jick
H
,
Derby
LE
,
Myers
MW
,
Vasilakis
C
,
Newton
KM
.
Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
.
Lancet
 0140-6736
1996
;
348
(
9033
):
981
3
.
34.
Varas-Lorenzo
C
,
Garcia-Rodriguez
LA
,
Cattaruzzi
C
,
Troncon
MG
,
Agostinis
L
,
Perez-Gutthann
S
.
Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe
.
Am J Epidemiol
 0002-9262
1998
;
147
(
4
):
387
90
.
35.
Simioni
P
,
Prandoni
P
,
Lensing
AW
,
Scudeller
A
,
Sardella
C
,
Prins
MH
, et al
.
The risk of recurrent venous thromboembolism in patients with an Arg506→ Gln mutation in the gene for factor V (factor V Leiden)
.
N Engl J Med
 0028-4793
1997
;
336
(
6
):
399
403
.
36.
Ridker
PM
,
Hennekens
CH
,
Lindpaintner
K
,
Stampfer
MJ
,
Eisenberg
PR
,
Miletich
JP
.
Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
.
N Engl J Med
 0028-4793
1995
;
332
(
14
):
912
7
.
37.
Griffin
JH
,
Evatt
B
,
Wideman
C
,
Fernandez
JA
.
Anticoagulant protein C pathway defective in majority of thrombophilic patients
.
Blood
 0006-4971
1993
;
82
(
7
):
1989
93
.
38.
Heijmans
BT
,
Westendorp
RG
,
Knook
DL
,
Kluft
C
,
Slagboom
PE
.
The risk of mortality and the factor V Leiden mutation in a population-based cohort
.
Thromb Haemost
 0340-6245
1998
;
80
(
4
):
607
9
.
39.
Dilley
A
,
Austin
H
,
Hooper
WC
,
El-Jamil
M
,
Whitsett
C
,
Wenger
NK
, et al
.
Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects
.
J Lab Clin Med
 0022-2143
1998
;
132
(
6
):
452
5
.
40.
Rees
DC
.
The population genetics of factor V Leiden (Arg506Gln)
.
Br J Haematol
 0007-1137
1996
;
95
(
4
):
579
86
.
41.
Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception
.
Lancet
 0140-6736
1995
;
346
(
8990
):
1575
82
.
42.
Jick
H
,
Jick
SS
,
Gurewich
V
,
Myers
MW
,
Vasilakis
C
.
Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components
.
Lancet
 0140-6736
1995
;
346
(
8990
):
1589
93
.
43.
Lewis
MA
,
Heinemann
LA
,
MacRae
KD
,
Bruppacher
R
,
Spitzer
WO
.
The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women
.
Contraception
 0010-7824
1996
;
54
(
1
):
5
13
.
44.
Vandenbroucke
JP
,
Koster
T
,
Briet
E
,
Reitsma
PH
,
Bertina
RM
,
Rosendaal
FR
.
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
.
Lancet
 0140-6736
1994
;
344
(
8935
):
1453
7
.
45.
Rozen
R
.
Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR)
.
Thromb Haemost
 0340-6245
1997
;
78
(
1
):
523
6
.
46.
Clarke
R
,
Daly
L
,
Robinson
K
,
Naughten
E
,
Cahalane
S
,
Fowler
B
, et al
Hyperhomocysteinemia: an independent risk factor for vascular disease
.
N Engl J Med
 0028-4793
1991
;
324
(
17
):
1149
55
.
47.
van der Put
NM
,
van den Heuvel
LP
,
Steegers-Theunissen
RP
,
Trijbels
FJ
,
Eskes
TK
,
Mariman
EC
, et al
Decreased methylene tetrahydrofolate reductase activity due to the 677C → T mutation in families with spina bifida offspring
.
J Mol Med
 0946-2716
1996
;
74
(
11
):
691
4
.
48.
Jacques
PF
,
Bostom
AG
,
Williams
RR
,
Ellison
RC
,
Eckfeldt
JH
,
Rosenberg
IH
, et al
.
Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations
.
Circulation
 0009-7322
1996
;
93
(
1
):
7
9
.
49.
Guttormsen
AB
,
Ueland
PM
,
Nesthus
I
,
Nygard
O
,
Schneede
J
,
Vollset
SE
, et al
.
Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> or = 40 micromol/liter). The Hordaland Homocysteine Study
.
J Clin Invest
 0021-9738
1996
;
98
(
9
):
2174
83
.
50.
Pectasides
D
,
Tsavdaridis
D
,
Aggouridaki
C
,
Tsavdaridou
V
,
Visvikis
A
,
Tsatalas
K
, et al
.
Effects on blood coagulation of adjuvant CNF (cyclophosphamide, novantrone, 5-fluorouracil) chemotherapy in stage II breast cancer patients
.
Anticancer Res
 0250-7005
1999
;
19
(
4C
):
3521
6
.
51.
Levine
MN
,
Gent
M
,
Hirsh
J
,
Arnold
A
,
Goodyear
MD
,
Hryniuk
W
, et al
.
The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer
.
N Engl J Med
 0028-4793
1988
;
318
(
7
):
404
7
.
52.
Rogers
JS
, 2nd
,
Murgo
AJ
,
Fontana
JA
,
Raich
PC
.
Chemotherapy for breast cancer decreases plasma protein C and protein S
.
J Clin Oncol
 0732-183X
1988
;
6
(
2
):
276
81
.
53.
Koeleman
BP
,
Reitsma
PH
,
Bertina
RM
.
Familial thrombophilia: a complex genetic disorder
.
Semin Hematol
 0037-1963
1997
;
34
(
3
):
256
64
.
54.
Ridker
PM
,
Hennekens
CH
,
Selhub
J
,
Miletich
JP
,
Malinow
MR
,
Stampfer
MJ
.
Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism
.
Circulation
 0009-7322
1997
;
95
(
7
):
1777
82
.
55.
Goldhaber
S
.
Pulmonary emboli
.
New England Journal of Medicine
 0028-4793
1998
;
339
(
2
):
93
104
.
56.
Juul
K
,
Tybjaerg-Hansen
A
,
Schnohr
P
,
Nordestgaard
BG
.
Factor V Leiden and the risk for venous thromboembolism in the adult Danish population
.
Ann Intern Med
 0003-4819
2004
;
140
(
5
):
330
7
.
This content is only available via PDF.
You do not currently have access to this content.